Articles tagged with: Maintenance Therapy
Press Releases»
- Oral REVLIMID® is the first and only medicine licensed in Europe for use as post-autologous stem cell transplantation maintenance therapy in multiple myeloma
- The new indication expands the availability of REVLIMID® across the disease continuum of multiple myeloma
Boudry, Switzerland (Press Release) – Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that the European Commission (EC) has approved REVLIMID® (lenalidomide) as monotherapy for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation (ASCT). REVLIMID® is the first and only licensed maintenance treatment available to these patients.
The REVLIMID® Marketing Authorisation has been updated to include this new indication, which expands on the existing multiple myeloma indications as …
Press Releases»
- REVLIMID is the first and only treatment approved for maintenance following auto-HSCT
- Updated data from two large, randomized, controlled studies demonstrated median progression-free survival (PFS) advantages of 3.8 and 1.9 years, respectively, in favor of patients receiving REVLIMID compared to no maintenance
- Median overall survival (OS) for patients receiving REVLIMID in each study was 9.3 years and 8.8 years, respectively, compared to 7 and 7.3 years for no maintenance in a descriptive analysis (studies not powered for OS)
- Approval enables Celgene to provide patients with treatment options across the multiple myeloma spectrum
Summit, NJ (Press Release) – Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has expanded the existing indication for REVLIMID (lenalidomide) 10 mg capsules to include use for patients with multiple myeloma as maintenance therapy following autologous hematopoietic stem cell transplant (auto-HSCT). The expanded indication makes REVLIMID the first and only treatment to receive FDA approval for maintenance use following auto-HSCT.
“Autologous stem cell transplant after induction therapy is …
Opinion»

During my 25-year career as a boy’s head basketball coach, I found the most satisfying (and most important) part of coaching was planning and devising game plans.
Putting my knowledge and experience to test to give my teams the best chance of winning was challenging and time consuming, but also enjoyable and exciting. Equally enjoyable and exciting was making adjustments to the game plan during the course of the game.
At times the game plan worked to perfection. Sometimes, the plan had to be adjusted immediately. With my better teams, the game plans varied …
Press Releases»
- REVLIMID® is the first and only medicine granted positive CHMP opinion for post-Autologous Stem Cell Transplantation (ASCT) maintenance therapy in MM
- The new indication expands the availability of REVLIMID® across the disease continuum of MM
Boudry, Switzerland (Press Release) – Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of REVLIMID® as monotherapy for the maintenance treatment of adult patients with newly diagnosed multiple myeloma (MM) who have undergone autologous stem cell transplantation (ASCT). Once approved by the European Commission, REVLIMID® will be the first and only licensed maintenance treatment available to …
Opinion»

I have been off treatment for my multiple myeloma for about six months, so I thought this would be a good time to evaluate where things stand.
First, a short recap for those who have not followed my story.
I was diagnosed with multiple myeloma at the end of June in 2013. Almost immediately, I began what turned out to be six cycles of Velcade (bortezomib), Revlimid (lenalidomide), and dexamethasone (Decadron). This regimen put me into what appeared to be complete remission. I phrase it that …
News»

This year’s American Society of Clinical Oncology (ASCO) annual meeting began the morning of last Friday, and the meeting will run through Tuesday.
Multiple myeloma-related presentations are taking place every day of the meeting. Friday, however, was the busiest day at the meeting in terms of oral presentations with new myeloma-related research. There were nine such presentations during a single afternoon session focused on multiple myeloma.
In addition, there were myeloma-related education session presentations on Saturday, yesterday, and today. There also was a late-breaking abstract session yesterday (Sunday) with one presentation that …
Opinion»

I just returned from a long trip to Europe, and boy do I feel refreshed! The reason I think I feel so good is that I took a holiday not just from work and the mundane problems of home, but I also took a holiday from my multiple myeloma.
I once again find myself feeling guilty for being one of the healthiest guys in the myeloma ward, so let me explain.
My wife and I spent about three weeks in Switzerland and Italy without the kids. It was a great trip. I …